Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study.

Haohua JiangYujing LiYanan WangBenkun ZouYa ChenYanwei ZhangHatim HusainFabien ForestFangfei QianLele ZhangChao ZhouHongyu LiuDanni WangWei ZhangJun LuBaohui Han

Published in: Translational lung cancer research (2024)

Despite having potential survival disadvantage compared with other NSCLC patients, rare KRAS-mutant patients (other than G12A, C, D, V) could benefit specifically from ICI-based therapy and survival outcomes are correlated with PD-L1 expression.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
small cell lung cancer
peritoneal dialysis
prognostic factors
epidermal growth factor receptor
patient reported outcomes
mesenchymal stem cells
smoking cessation
replacement therapy